BioTuesdays

Category - Developments

Armata Pharmaceuticals
Developments

FDA grants QIDP for Armata’s AP-SA02

Armata Pharmaceuticals (NYSE American: ARMP) has announced that the FDA has granted AP-SA02 Qualified Infectious Disease Product (QIDP) designation for intravenous use in the adjunct treatment of complicated bacteremia...

February 23, 2026
Acrivon Therapeutics Logo
Developments

Acrivon launches internal CLIA-certified lab

Acrivon Therapeutics (NASDAQ: ACRV) has announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory, located on premises in...

February 18, 2026
Developments

IP Australia grants Klotho 18 claims for s-KL

Klotho Neurosciences (NASDAQ: KLTO) has announced that IP Australia has accepted 18 claims within its patent application covering the composition and use of its human secreted Klotho protein, s-KL isoform. The patent...

February 18, 2026
Precision Biosciences
Developments

FDA clears Precision’s IND for PBGENE-DMD

Precision BioSciences (NASDAQ: DTIL) has announced that the FDA has granted a Study May Proceed notification, allowing initiation of clinical trial site activation for the Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD in...

February 13, 2026
BioSyent
Developments

BioSyent to acquire Oral Science

BioSyent (TSXV: RX) has entered into a Share Purchase Agreement to acquire closely held Oral Science, a Canadian distributor of specialized healthcare products for dental hygiene and oral health based in Brossard...

February 10, 2026